Skip to main content
. 2000 Feb 18;97(5):2168–2173. doi: 10.1073/pnas.040554597

Figure 2.

Figure 2

Clinical status of a C57BL/6 mouse with EAMG before and after treatment with the dual analog. (A) A representative C57BL/6 mouse after immunization and boost with Torpedo AChR α-subunit. The myasthenic decrements determined at that time by electromyography (see Materials and Methods) are shown. (B) The same mouse after 6 wk of treatment with the dual analog administered orally. No myasthenic decrement could be detected by electromyography.